Abstract 1760: ADI-PEG20 and GC7 as a novel anti-metabolite strategy for the treatment of malignant pleural mesothelioma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1760
Abstract: Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with less than 10% of patients surviving 5-years from diagnosis. Arginine deprivation using pegylated arginine deiminase (ADI-PEG20) is a novel treatment for mesothelioma deficient in the… read more here.
Keywords: gc7; adi peg20; peg20; cell lines ... See more keywords
Bench-to-Bedside Studies of Arginine Deprivation in Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28052150
Abstract: Arginine is a semi-essential amino acid which becomes wholly essential in many cancers commonly due to the functional loss of Argininosuccinate Synthetase 1 (ASS1). As arginine is vital for a plethora of cellular processes, its… read more here.
Keywords: bench bedside; arginine deprivation; deprivation; adi peg20 ... See more keywords
Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines
Sign Up to like & getrecommendations! Published in 2018 at "Oncology Letters"
DOI: 10.3892/ol.2018.8807
Abstract: Cholangiocarcinoma (CCA) is a severe cancer with poor prognosis. The aim of the present study was to explore the expression of argininosuccinate synthetase (ASS), as well as the possibility of using pegylated arginine deiminase (ADI-PEG20)… read more here.
Keywords: peg20 treatment; cca; expression; cell ... See more keywords